Axial: https://linktr.ee/axialxyz
Axial partners with great founders and inventors. We invest in early-stage life sciences companies such as Appia Bio, Seranova Bio, Delix Therapeutics, Simcha Therapeutics, among others often when they are no more than an idea. We are fanatical about helping the rare inventor who is compelled to build their own enduring business. If you or someone you know has a great idea or company in life sciences, Axial would be excited to get to know you and possibly invest in your vision and company . We are excited to be in business with you - email us at info@axialvc.com
ChemoCentryx was acquired by Amgen for ~$3.8B in 2022. Founded in 1996, by Thomas Schall who discovered many of the 50 chemokines, the company was started to drug them, the trafficking control system for immune system & develop once-daily, orally-available drugs for autoimmunity.
Chemokines act as signposts to get different immune cells into certain organs. ChemoCentryx built a pipeline to target chemokines & receptors to treat autoimmunity & inflammatory diseases. This led to the development/approval of avacopan insevere active ANCA-associated vasculitis.
Most autoimmune medicines are either injectable or given through IV. By creating a more user-friendly drug, ChemoCentryx is positioned to capture large parts of the autoimmunity market. The company has candidates in development for hidradenitis suppurativa, C3G, & more.
Thomas Schall is a template for all founders & inventors to follow and ChemoCentryx is beginning to transform the lives of patients https://www.amgen.com/newsroom/press-releases/2022/08/amgen-to-acquire-chemocentryx-for-$4-billion-in-cash